ZYME Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Zymeworks Inc. (ZYME) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price declines and mixed sentiment, the company's strong growth potential, analyst optimism, and promising drug pipeline make it a compelling long-term opportunity.
The technical indicators are moderately bullish. The MACD is positive and expanding, suggesting upward momentum. The RSI is neutral at 61.536, and the moving averages (SMA_5 > SMA_20 > SMA_200) are bullish. The stock is trading near its pivot point of 23.255, with key resistance at 24.275 and support at 22.235.
Analysts are optimistic, with multiple Buy ratings and price targets ranging from $32 to $40, highlighting the potential of Zymeworks' drug pipeline.
The company's FDA-approved product, zanidatamab, and its potential second approval in gastroesophageal adenocarcinoma are seen as significant growth drivers.
Revenue increased by 72.59% YoY in Q3 2025, indicating strong top-line growth.
Redmile Group reduced its stake in Zymeworks, reflecting decreased confidence from a major investor.
Net income and EPS declined significantly YoY in Q3 2025, raising concerns about profitability.
The stock has shown a downward trend in the short term, with a -2.52% regular market change and -1.51% pre-market change.
In Q3 2025, Zymeworks reported a 72.59% YoY increase in revenue to $27.61 million. However, net income dropped by 34.33% YoY to -$19.60 million, and EPS fell by 33.33% YoY to -0.26. Gross margin remained strong at 100%.
Analysts are bullish on Zymeworks. Truist initiated coverage with a Buy rating and a $40 price target, citing the company's shift to a royalty-focused business and its promising drug pipeline. Wells Fargo upgraded the stock to Overweight with a $33 price target, highlighting the potential of its gastroesophageal adenocarcinoma treatment. Citizens JMP initiated coverage with an Outperform rating and a $32 price target, emphasizing the FDA approval of zanidatamab and its future prospects.
